AUTHORS
David Justus, MD, Tracy Huynh, BA2, Kimberly Ching, BA3, Ellen Proeung, PA4, Carly Howard, RN5, Tara Kelly, MS, BSN, RN, CPN6, Jessica Clark, RN, BSN, CPN7, Jacqui Lynch, BSN, RN, CPN8, Zaria McClendon, BSN, RN9, Bernadette Benn, BSN, RN10, Carly Campbell, BSN, RN11, Jennifer Fortin, MSN, RN, NEA-BC12, John P Manis, MD13
AFFILIATIONS
1 Department of Laboratory Medicine, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, United States
2 Department of Laboratory Medicine, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, United States
3 Department of Laboratory Medicine, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, United States
4 Department of Laboratory Medicine, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, United States
5 Department of Nursing-Patient Care Operations, Boston Children's Hospital, Boston, Massachusetts, United States
6 Department of Nursing-Patient Care Operations, Boston Children's Hospital, Boston, Massachusetts, United States
7 Department of Nursing-Patient Care Operations, Boston Children's Hospital, Boston, Massachusetts, United States
8 Department of Nursing-Patient Care Operations, Boston Children's Hospital, Boston, Massachusetts, United States
9 Department of Nursing-Patient Care Operations, Boston Children's Hospital, Boston, Massachusetts, United States
10 Department of Nursing-Patient Care Operations, Boston Children's Hospital, Boston, Massachusetts, United States
11 Department of Nursing-Patient Care Operations, Boston Children's Hospital, Boston, Massachusetts, United States
12 Department of Nursing-Patient Care Operations, Boston Children's Hospital, Boston, Massachusetts, United States
13 Department of Laboratory Medicine, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, United States
ABSTRACT
Background: Most patients with sickle cell disease (SCD) receive multiple transfusions during their lifetime, predominantly as episodic or chronic simple transfusions. Chronic transfusion is complicated by iron overload, alloimmunization, and limited RBC unit availability. Judicious use of the fewest RBC units needed to achieve a therapeutically meaningful hemoglobin S (HbS) decrease is essential, particularly for alloimmunized patients with limited compatible RBC supply who may be considering gene therapies requiring intensive transfusion support. Apheresis instrument parameters are not standardized, and current practices and algorithms often result in more RBCs being transfused than needed to achieve HbS targets. Furthermore, peripheral blood HbS values at the time of RCE are not always readily available, limiting the entry of precise data into apheresis calculations. To address this gap, we evaluated manufacturer-recommended algorithms and characterized HbS decrease kinetics during RBC exchange using real-time measurements, aiming to inform patient- and procedure-specific device settings that reduce blood use.
Methods: To determine net HbS reduction relative to RBC volume exchanged and the temporal performance of automated red cell exchange (RCE), we evaluated 11 procedures in 7 patients with SCD. Six patients underwent RCE within a chronic transfusion program, and one underwent urgent RCE. Exchange volume and end-procedure fraction of cells remaining (FCR) were calculated by device-specific software based on height, weight, and pre-procedure hematocrit, with the most commonly entered FCR of 30% and post-procedure hematocrit of 30%. Peripheral HbS was measured before RCE and at 25%, 50%, 75%, and 100% of calculated exchange volume using a research-use-only point-of-care HbS analyzer (Gazelle,Hemex). HbS in the RCE effluent (waste) from the instrument was also measured in tandem. HbS reduction was calculated within each quartile. Quartile reductions were compared using the Friedman test, third- vs final-quartile reductions using the paired Wilcoxon signed-rank test, and repeat procedures were summarized at the patient level.
Results: Across 11 RCE procedures in 7 patients (median age, 19 years [17–22], median total patient blood volume, 4,474 mL [3,281–5,137]), the median planned RBC exchange volume based on standard instrument settings was 2,008 mL RBCs (1,572-2,960), or about 7 units (6-10). Median HbS was 33.0% pre-RCE and 26.0%, 20.0%, 14.0%, and 13.8% after the 25%, 50%, 75%, and 100% exchange quartiles. Median absolute HbS reductions per quartile were 10.0, 9.0, 6.0, and 1.1 percentage points (relative reductions 23.8%, 30.6%, 31%, 12.5%). Absolute and relative HbS reductions differed significantly across quartiles (Friedman P=.0003 and P=.0085, respectively). The absolute reduction during the final-quartile was smaller than during the third (1.1 vs 6.0 points, P<.001) and did not differ from zero (P=.58). This pattern persisted with repeat procedures by patient (P=.008), consistent with declining efficiency as peripheral HbS fell. A corresponding rise in measured waste-product HbA reflected donor-blood recirculation, greatest near the end of exchange. The final quartile accounted for a median 502 mL of RBCs (393-740), nearly 2 units (1.5-2.5). Median pre- and post-procedure hemoglobin levels were 10.0 g/dL (5.3-11.2) and 10.3 g/dL (8.2-11.1); hematocrits were 28.5% (14.3-32.7) and 29.4% (23.8-32.0), respectively.
Conclusion: Real-time HbS measurement during automated RCE showed nonlinear reduction, with only marginal gains in the final exchange-volume quartile. Re-evaluating exchange volume based on these kinetics and real-time values suggests more than 25% could be saved per procedure, relevant amid a contracting blood supply and growing antigen-matching needs for patients with SCD. These pilot data are informing our prospective trial testing whether reduced RBC usage maintains HbS and hematocrit targets in chronic exchange patients, with outcomes including RBC volume/units saved, iron balance, alloimmunization, transfusion reactions, and safety. Reducing RBC exposure may be especially valuable for alloimmunized patients, potentially expanding access to transformative therapies that otherwise require intensive transfusion support. If validated, this adaptive, tailored, patient-specific strategy could conserve RBCs, expand RCE access, and extend to other transfusion modalities.
DISCLOSURES
David Justus, MD: No relevant conflicts of interest to declare.